Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
TEVA PHARMACEUTICAL INDUSTRIES (NY: TEVA)
50.85 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 6:40 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open -
Bid (Size) 50.83 (700)
Ask (Size) 50.85 (1400)
Prev. Close 50.85
Today's Range 50.85 - 50.85
52wk Range 36.26 - 54.70
Shares Outstanding 946,868,125
Dividend Yield 0.68%
Performance
YTD
+26.30%
+26.30%
1 Month
+3.02%
+3.02%
3 Month
+15.54%
+15.54%
6 Month
+27.54%
+27.54%
1 Year
+31.57%
+31.57%
Top News
More News
Philadelphia Parkinson's Disease CommUNITY Rallied At Rocky Statue Launching New Public Awareness Campaign From The Parkinson's Unity Walk Organization And Teva
April 17, 2014
"CommUNITY: Carrying the PD Torch" Campaign Seeks to Empower and Provide Support for PD Patients Read More
from PR Newswire
Teva Settles Patent Litigation with Pfizer on Celebrex®
April 17, 2014
from Business Wire News Releases
More News
Read More
Teva Announces Launch of Generic Lunesta® Tablets in the United States
April 15, 2014
from Business Wire News Releases
UPDATE 1-Teva willing to post bond to suspend decision on Copaxone
April 17, 2014
category companyNews
from Reuters: Company News
Teva willing to post $500 million bond in Copaxone case
April 17, 2014
category companyNews
from Reuters: Company News
FDA wants stronger warning labels for long-acting opioids
April 17, 2014
category companyNews
from Reuters: Company News
UPDATE 2-Teva settles patent suit with Pfizer over Celebrex
April 17, 2014
category companyNews
from Reuters: Company News
Teva, Pfizer settle patent lawsuit over painkiller Celebrex
April 17, 2014
category companyNews
from Reuters: Company News
Teva Pharma (TEVA), Pfizer (PFE) Settle Over Generic Celebrex
April 17, 2014
from StreetInsider.com News Articles
Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received Tenative FDA Approval for All Strengths; May Start Generic Versions in December
April 17, 2014
category Press Releases , Benzinga , TEVA , and 2 more.
from Benzinga
Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing
April 16, 2014
category Benzinga , TEVA , Shibani Malhotra , and 3 more.
from Benzinga
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here